RxSight, Inc.
RXSTRxSight, Inc. is a commercial-stage medical technology company that provides a proprietary light-adjustable intraocular lens system for patients undergoing cataract surgery.
Earnings
Next report
Aug 5, 2026 (In 1 week)Valuation & ratios
Segments
By product
Competitors
By market cap
By revenue growth
By net margin
Profile
RxSight, Inc. is a commercial-stage medical technology company that provides a proprietary light-adjustable intraocular lens system for patients undergoing cataract surgery. Its core value proposition is the ability for surgeons to customize and optimize a patient's visual acuity post-surgery through non-invasive light treatments, eliminating the preoperative guesswork associated with conventional fixed-power premium lenses.
The company holds a unique market position as the provider of the first and only FDA-approved intraocular lens that can be adjusted post-implantation.
Questions, answered.
- What is RxSight, Inc.'s market cap?
- RxSight, Inc. (RXST) has a market capitalization of $233.5M and trades on NASDAQ.
- What is RxSight, Inc.'s revenue and profitability?
- RxSight, Inc. generated $127.5M in trailing twelve-month revenue with a net loss of $46.6M, representing a net margin of -36.6%. Gross margin stands at 77.0%, with free cash flow of -$21.6M. These figures are based on the Q1 2026 filing.
- Who are RxSight, Inc.'s competitors?
- RxSight, Inc.'s key competitors include Alcon Inc., Johnson & Johnson, LENSAR, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Who does RxSight, Inc. partner with?
- RxSight, Inc.'s notable partners include QAD, Inc., Haffey & Company.
- Where is RxSight, Inc. headquartered?
- RxSight, Inc. is headquartered in United States of America and employs approximately 374 people. It has been publicly traded since 2021.
